Generic Name and Formulations:
Losartan potassium, hydrochlorothiazide; 50mg/12.5mg, 100mg/12.5mg, 100mg/25mg; tabs.
Merck & Co., Inc.
Indications for HYZAAR:
Hypertension (not for initial therapy unless HTN is severe). To reduce stroke in hypertensive patients with left ventricular hypertrophy (LVH); this benefit may not apply to black patients.
≥18yrs: One 50/12.5mg tab once daily; may increase after about 3 weeks (2–4 weeks for severe HTN) to two 50/12.5mg tabs once daily or one 100/25mg tab once daily. Titrate components: see full labeling. HTN with LVH: switch from losartan monotherapy (see full labeling). Severe renal impairment (CrCl<30mL/min): not recommended.
<18yrs: not established.
Angiotensin II receptor blocker + thiazide diuretic.
Anuria. Sulfonamide allergy. Concomitant aliskiren in patients with diabetes.
Fetal toxicity may develop; discontinue if pregnancy is detected. Correct salt/volume depletion before starting therapy, or reduce initial dose. Renal impairment: monitor for worsening renal function. Hepatic impairment requiring titration with losartan: not recommended. Severe CHF. Renal artery stenosis. Asthma. SLE. Gout. Diabetes. Postsympathectomy. Acute myopia. Secondary angle-closure glaucoma. Pregnancy (Cat.D). Nursing mothers: not recommended.
See Contraindications. Hyperkalemia with K+ supplements, K+ sparing diuretics, K+ containing salt substitutes. Potentiated by fluconazole. Antagonized by rifampin. May be antagonized by, and renal toxicity potentiated by NSAIDs, including selective COX-2 inhibitors (monitor renal function periodically in elderly and/or volume-depleted). Dual inhibition of the renin-angiotensin system with ARBs, ACEIs, or aliskiren may increase risk of hypotension, hyperkalemia, renal function changes; monitor closely. Avoid concomitant aliskiren in renal impairment (CrCl <60mL/min). Orthostatic hypotension with alcohol, other CNS depressants. Potentiates other antihypertensives, tubocurarine. Hypokalemia with corticosteroids, ACTH. May antagonize pressor amines (eg, norepinephrine), cholestyramine, colestipol resins. Adjust antihyperglycemics. May increase digitalis, lithium toxicity (monitor). May interfere with parathyroid tests.
Dizziness, abdominal pain, palpitations, back pain, sinusitis, cough, upper respiratory infection, rash, hyperkalemia; angioedema, syncope (discontinue if occurs), rhabdomyolysis (rare).
Hepatic (CYP2C9, 3A4).
Tabs—30, 90, 1000
Sign Up for Free e-newsletters
Cancer Therapy Advisor Articles
- Nivolumab Plus Ipilimumab Demonstrates Activity in Recurrent Glioblastoma
- mFOLFOX6 Plus Radiotherapy Results in Higher pCR in Rectal Cancer
- Anastrozole More Effective than Tamoxifen for Postmenopausal Women with Ductal Carcinoma
- Nivolumab Significantly Improves Outcomes in Advanced Melanoma
- Study Suggests Renal Cell Carcinoma Reprograms its Metabolism to Evade Immune System
- Vitamin D Levels and Risk for Pancreatic Cancer
- New Screening Method May Identify Twice As Many Women with Ovarian Cancer
- Head and Neck Cancers Treatment Regimens
- Nicotinamide Safe, Effective for Non-Melanoma Skin Cancer Prevention in High-Risk Patients
- Prostate Cancer Working Group Updates CRPC Clinical Trial Guidelines
- Panitumumab, Accelerated Fractionation RX Not Superior to Standard of Care in Head and Neck Cancer
- Complete Response Rate at 30 Months Correlates with Progression-Free Survival in Follicular Lymphoma
- Neratinib Improves Two-Year Survival in Breast Cancer After Adjuvant Chemo, Trastuzumab
- Palbociclib, Fulvestrant Improves Progression-Free Survival in HR+, HER2- Breast Cancer
- Denosumab Significantly Reduces Fractures in Postmenopausal Women with Breast Cancer
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|